SCHEMBL402266

SCHEMBL402266

CCOC(=O)c1ccc(OC(=O)CCCc2ccc(NC(=O)c3ccc(C)nc3-c3ccc(C(F)(F)F)cc3)c(C(=O)N(C)C)c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 1/20 0.43
NTRK2 Q16620 1/20 0.43
PLK1 P53350 1/20 0.38
MAOB P27338 1/20 0.37
KCNH2 Q12809 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
SLC22A2 O15244 1/20 0.35
TMPRSS2 O15393 1/20 0.35
F2 P00734 1/20 0.35
F10 P00742 1/20 0.35
PLG P00747 1/20 0.35
F12 P00748 1/20 0.35
PLAU P00749 1/20 0.35
PLAT P00750 1/20 0.35
KLKB1 P03952 1/20 0.35
CYP1A2 P05177 1/20 0.35
HPN P05981 1/20 0.35
CHRM2 P08172 1/20 0.35
CYP2D6 P10635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10205546 0.94 NTRK1 (0.42) NTRK1NTRK2PLK1KCNH2MAPT
SCHEMBL401089 0.94 NTRK1 (0.41) NTRK1NTRK2PLK1MAPTSUV39H1
SCHEMBL5318000 0.92 NTRK1 (0.43) NTRK1NTRK2PLK1KCNH2SUV39H1
SCHEMBL402484 0.92 NTRK1 (0.40) NTRK1NTRK2PLK1KCNH2SUV39H1
SCHEMBL401283 0.92 NTRK1 (0.40) NTRK1NTRK2PLK1KCNH2SUV39H1
SCHEMBL6091314 0.91 NTRK1 (0.41) NTRK1NTRK2PLK1MAOBKCNH2
SCHEMBL10205609 0.91 NTRK1 (0.42) NTRK1NTRK2PLK1MAOBKCNH2
SCHEMBL403623 0.91 NTRK1 (0.39) NTRK1NTRK2KCNH2
SCHEMBL404114 0.90 PLK1 (0.41) NTRK1NTRK2PLK1PPARGPPARA
Sulfuric Acid SCHEMBL402780 0.90 NTRK1 (0.39) NTRK1NTRK2PLK1KCNH2SUV39H1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1803452-A1 ESTER DERIVATIVE AND PHARMACEUTICAL USE THEREOF Japan Tobacco, Inc. (JP) 2007-07-04 EP claimed
US-20060089392-A1 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2006-04-27 US claimed
US-8101774-B2 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2012-01-24 US disclosed
US-8101774-B2 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2012-01-24 US disclosed
US-8101774-B2 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2012-01-24 US disclosed
EP-1803452-A1 ESTER DERIVATIVE AND PHARMACEUTICAL USE THEREOF Japan Tobacco, Inc. (JP) 2007-07-04 EP disclosed
US-20060089392-A1 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2006-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089392-A1 Ester derivatives and medicinal use thereof MTTP, CETP, LIPA NTRK1 3420/4885NTRK2 2775/4885PLK1 4544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.